Peptide reference

Partial sequence of body protection compound derived from human gastric juice. Extensive research on tendon, muscle, and gut repair via multiple pathways.

Dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist. SURMOUNT trials demonstrated up to 22.5% body weight reduction.

Triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2b showed ~24% body weight reduction at 48 weeks.

Synthetic fragment of thymosin beta-4. Promotes actin upregulation, cell migration, and angiogenesis for tissue repair.

GHRH analogue available with or without Drug Affinity Complex (DAC). Without DAC: short pulsatile release. With DAC: extended half-life of ~8 days.

Selective GHRP with minimal cortisol and prolactin stimulation. Typically stacked with CJC-1295 for synergistic GH release.

Synthetic analogue of endogenous GHRH containing the first 29 amino acids. Stimulates pituitary GH release via natural signaling pathways.

Naturally occurring copper peptide with demonstrated effects on wound healing, collagen synthesis, and stem cell activation.

Melanocortin receptor agonist acting centrally on MC3R and MC4R. FDA-approved (Vyleesi) for hypoactive sexual desire disorder.

Synthetic tetrapeptide derived from epithalamin. Research focuses on telomere elongation and pineal gland regulation.